Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
86%
Rituximab
73%
Diseases
72%
Radiation Therapy
62%
Progression Free Survival
53%
Overall Survival
52%
Non-Hodgkin Lymphoma
52%
Mantle Cell Lymphoma
44%
Follicular Lymphoma
41%
Large-Cell Lymphoma
37%
B-Cell Lymphoma
32%
Hodgkin's Lymphoma
29%
Malignant Neoplasm
28%
Doxorubicin
27%
Survival Rate
26%
Cyclophosphamide
26%
B Cell
24%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
21%
MALT Lymphoma
21%
Ibrutinib
19%
Vincristine
18%
Classical Hodgkin Lymphoma
17%
Lenalidomide
17%
Chimeric Antigen Receptor T-Cell Immunotherapy
16%
Positron Emission Tomography-Computed Tomography
16%
positron emission tomographic scan
15%
Lymphocytic Lymphoma
13%
Methotrexate
13%
International Prognostic Index
13%
Adverse Event
12%
Allogeneic Stem Cell Transplantation
12%
Arm
12%
Central Nervous System
12%
Prednisone
12%
Lymphoma Cell
12%
Burkitt's Lymphoma
12%
Axicabtagene Ciloleucel
12%
Phase II Trials
12%
Neoplasm
12%
Hazard Ratio
11%
T Cell
11%
Disease Exacerbation
11%
Oncology
10%
Autologous Stem Cell Transplantation
10%
Cytarabine
10%
B-Cell Chronic Lymphocytic Leukemia
10%
Peripheral T-Cell Lymphoma
10%
Systemic Therapy
9%
Fludarabine
9%
Failure Free Survival
9%
Keyphrases
Rituximab
79%
Diffuse Large B-cell Lymphoma (DLBCL)
72%
Mantle Cell Lymphoma
58%
Relapsed or Refractory
52%
Follicular Lymphoma
45%
Progression-free Survival
42%
Complete Response
39%
Cyclophosphamide
33%
Overall Survival
31%
Phase II Study
30%
Radiation Therapy
30%
Chemotherapy
29%
Lymphoma
28%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
28%
Large B-cell Lymphoma
27%
Doxorubicin
25%
Non-Hodgkin Lymphoma
24%
Lymphoma Patients
23%
B-cell Lymphoma
23%
R-CHOP
21%
Newly Diagnosed
19%
Phase II Trial
19%
Overall Response Rate
19%
Cytarabine
18%
Chimeric Antigen Receptor T-cell Therapy
18%
Hyper-CVAD
17%
Partial Response
16%
Bortezomib
15%
High Risk
15%
NCCN Guidelines
15%
Advanced Stage
14%
MD Anderson Cancer Center
14%
Radiotherapy
14%
Ibrutinib
14%
Prednisone
14%
B-cell non-Hodgkin Lymphoma (B-NHL)
14%
Fludarabine
13%
Failure-free Survival
13%
Methotrexate
13%
Confidence Interval
13%
Lenalidomide
12%
Peripheral T-cell Lymphoma
12%
T Cells
12%
International Prognostic Index
12%
Positron Emission Tomography-computed Tomography (PET-CT)
12%
Marginal Zone Lymphoma
12%
Pentostatin
11%
Previously Untreated
11%
Disease Progression
11%
Overall Survival Rate
11%
Pharmacology, Toxicology and Pharmaceutical Science
Rituximab
100%
Diffuse Large B Cell Lymphoma
56%
Nonhodgkin Lymphoma
50%
Mantle Cell Lymphoma
49%
Chemotherapy
44%
Diseases
43%
Cyclophosphamide
38%
Progression Free Survival
38%
Overall Survival
34%
Doxorubicin
31%
Follicular Lymphoma
29%
Malignant Neoplasm
28%
Vincristine
28%
Remission
23%
Survival Rate
22%
Cytarabine
21%
Methotrexate
21%
Large Cell Lymphoma
20%
Chimeric Antigen Receptor
19%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
18%
Dexamethasone
18%
Lenalidomide
17%
Prednisone
16%
Failure Free Survival
15%
Hodgkin Disease
14%
Bortezomib
14%
Phase II Trials
14%
B Cell Lymphoma
13%
Ibrutinib
13%
Adverse Event
12%
Neoplasm
11%
Fludarabine
11%
Clinical Trial
11%
Neutropenia
10%
Thrombocytopenia
10%
Classical Hodgkin Lymphoma
9%
Obinutuzumab
9%
Angiofollicular Lymph Node Hyperplasia
9%
Disease Exacerbation
9%
Etoposide
9%
Event Free Survival
8%
Axicabtagene Ciloleucel
7%
Monoclonal Antibody
7%
Siltuximab
7%
Denileukin Diftitox
7%
Danvatirsen
7%
Pentostatin
7%
Inotuzumab Ozogamicin
7%
Interleukin 6
7%
Myelodysplastic Syndrome
6%